source
- Menarini secures European rights to Chinese GLP-1 obesity drugMenarini Group, a large family‑owned pharmaceutical company in Italy, has obtained the European commercial rights to a GLP‑1 agonist developed by China’s Gan & Lee. The agreement gives Menarini a…
- Eli Lilly stops disclosing Phase 1 pipeline, prompting mixed reactionsEli Lilly announced that it will no longer publicly share details of its Phase 1 drug candidates. The policy shift comes as the company’s GLP-1 product continues to generate the highest sales among…